Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum.

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Food systems, nutrition, health and the environment

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised,

Effect of a bereavement support group on female adolescents' psychological health: a randomised controlled trial in South Africa Prof Tonya Renee Thurman,

Volume 369, Issue 9563, Pages (March 2007)

Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in.

The commercial determinants of health

Helen Cox, Mark P Nicol The Lancet Infectious Diseases

The impact of megacities on health: preparing for a resilient future

Infections related to totally implantable venous-access ports

DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection Dr Mihály Sulyok,

Volume 390, Issue 10092, Pages (July 2017)

Volume 392, Issue 10145, Pages (August 2018)

The number of privately treated tuberculosis cases in India: an estimation from drug sales data Dr Nimalan Arinaminpathy, DPhil, Deepak Batra, PGDM,

Mental health indicators associated with oil spill response and clean-up: cross-sectional analysis of the GuLF STUDY cohort Richard K Kwok, PhD, John.

Underestimate of annual malaria imports to Canada – Author reply

Threats to human health by great ocean garbage patches

The predicament of patients with suspected Ebola

Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax.

Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study Dr R McGready,

When less is more: how many doses of PCV are enough?

Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants:

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

Do air quality alerts benefit public health? New evidence from Canada

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial Martin J Boeree, PhD, Norbert.

Nicola Low, Joost H Smid The Lancet Public Health

Volume 392, Issue 10147, Pages (August 2018)

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection Dr Mihály Sulyok,

Volume 390, Issue 10092, Pages (July 2017)

Pregnancy outcomes in Liberian women who conceived after recovery from Ebola virus disease Mosoka P Fallah, Laura A Skrip, Bernice T Dahn, Tolbert G.

Effective cross-sector collaborations create sustainability

AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised,

Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised,

The effect of explosive remnants of war on global public health: a systematic mixed- studies review using narrative synthesis Alexandra Frost, MSc, Prof.

Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled.

Arnaud Chiolero The Lancet Public Health

Jonathan Broad, Matthew D Snape The Lancet Public Health

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised,

Volume 388, Issue 10063, Pages (December 2016)

Volume 4, Issue 6, Pages (June 2017)

Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta- analysis Prof Ric N Price, MD, Lorenz von Seidlein, PhD, Neena.

Food systems, nutrition, health and the environment

Sherif M Abdalla, Robert Bortolussi, Noni E MacDonald

The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis Prof Karen Hughes, PhD, Prof Mark A Bellis, DSc,

Exposure to improved nutrition from conception to age 2 years and adult cardiometabolic disease risk: a modelling study Nicole D Ford, PhD, Jere R Behrman,

Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis Robert J Commons, FRACP, Prof Julie.

Effect of a bereavement support group on female adolescents' psychological health: a randomised controlled trial in South Africa Prof Tonya Renee Thurman,

Volume 393, Issue 10172, Pages (February 2019)

Oral doxycycline for the prevention of postoperative trachomatous trichiasis in Ethiopia: a randomised, double-blind, placebo-controlled trial Esmael.

Muh Geot Wong, Vlado Perkovic The Lancet Diabetes & Endocrinology

Thank you to our diverse (but not diverse enough) reviewers

Volume 392, Issue 10160, Pages (November 2018)

Global burden of maternal and congenital syphilis in 2008 and 2012: a health systems modelling study N Saman Wijesooriya, MPH, Roger W Rochat, MD, Mary.

Volume 4, Issue 5, Pages (May 2017)

Artefenomel: a promising new antimalarial drug

Volume 6, Issue 3, Pages (March 2019)

Matthieu J Guitton The Lancet Planetary Health

Infections related to totally implantable venous-access ports

Spatial lifecourse epidemiology

Effect of a behaviour change intervention on the quality of peri-urban sanitation in Lusaka, Zambia: a randomised controlled trial James B Tidwell, PhD,

Task sharing with non-physician health-care workers for management of blood pressure in low-income and middle-income countries: a systematic review and.

Improving management of neonatal infections

Deriving a practical framework for the evaluation of health apps

Refining treatment choices for ADHD

Volume 6, Issue 7, Pages (July 2019)

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum.

Institutional challenges to achieving health equity in Ecuador

Sickle cell disease: a new era

Presentation transcript:

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study Alejandro Llanos-Cuentas, PhD, Martin Casapia, MPH, Raúl Chuquiyauri, PhD, Juan-Carlos Hinojosa, MD, Nicola Kerr, MA, Maria Rosario, PhD, Stephen Toovey, MD, Robert H Arch, PhD, Margaret A Phillips, PhD, Felix D Rozenberg, BA, Jade Bath, BA, Caroline L Ng, PhD, Annie N Cowell, MD, Elizabeth A Winzeler, PhD, David A Fidock, PhD, Mark Baker, PhD, Jörg J Möhrle, PhD, Rob Hooft van Huijsduijnen, PhD, Nathalie Gobeau, PhD, Nada Araeipour, MA, Nicole Andenmatten, PhD, Thomas Rückle, PhD, Stephan Duparc, MD The Lancet Infectious Diseases Volume 18, Issue 8, Pages 874-883 (August 2018) DOI: 10.1016/S1473-3099(18)30309-8 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 1 Trial design and patients ITT=intention-to-treat. The Lancet Infectious Diseases 2018 18, 874-883DOI: (10.1016/S1473-3099(18)30309-8) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 2 Parasitaemia in the patients with Plasmodium falciparum malaria Parasitaemia was measured by microscopy. Patients received a single oral dose at 0 h with 400 mg (A) or 250 mg (B) DSM265. Patient F2003 developed suspected bacteraemia, a serious, non-treatment-related adverse event, and was discontinued from the study. The Lancet Infectious Diseases 2018 18, 874-883DOI: (10.1016/S1473-3099(18)30309-8) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 3 Parasitaemia in the patients with Plasmodium vivax malaria Parasitaemia was measured by microscopy. Patients received a single oral dose at 0 h with 400 mg (A), 600 mg (B), or 800 mg (C) DSM265. The Lancet Infectious Diseases 2018 18, 874-883DOI: (10.1016/S1473-3099(18)30309-8) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions